These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25498778)

  • 21. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs.
    Ungar WJ; Costa V; Hancock-Howard R; Feldman BM; Laxer RM
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):111-9. PubMed ID: 20740607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period.
    Vilaiyuk S; Soponkanaporn S; Jaovisidha S; Benjaponpitak S; Manuyakorn W
    Int J Rheum Dis; 2016 Dec; 19(12):1342-1350. PubMed ID: 26176300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
    Niewerth M; Minden K; Klotsche J; Horneff G
    Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort.
    Guzman J; Henrey A; Loughin T; Berard RA; Shiff NJ; Jurencak R; Huber AM; Oen K; Gerhold K; Feldman BM; Scuccimarri R; Houghton K; Chédeville G; Morishita K; Lang B; Dancey P; Rosenberg AM; Barsalou J; Bruns A; Watanabe Duffy K; Benseler S; Duffy CM; Tucker LB;
    J Rheumatol; 2019 Jun; 46(6):628-635. PubMed ID: 30647178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis.
    Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM
    J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses.
    Aeschlimann FA; Chong SL; Lyons TW; Beinvogl BC; Góez-Mogollón LM; Tan S; Laxer RM
    J Pediatr; 2019 Jan; 204():162-171.e3. PubMed ID: 30318371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment.
    Harrison M; Marra C; Shojania K; Bansback N
    Rheumatology (Oxford); 2015 Oct; 54(10):1816-25. PubMed ID: 25989956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review.
    Shenoi S; Horneff G; Cidon M; Ramanan AV; Kimura Y; Quartier P; Foeldvari I; Zeft A; Lomax KG; Gregson J; Abma T; Campbell-Hill S; Weiss J; Patel D; Marinsek N; Wulffraat N
    Clin Exp Rheumatol; 2018; 36(5):920-928. PubMed ID: 29600940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis.
    Huang B; Qiu T; Chen C; Zhang Y; Seid M; Lovell D; Brunner HI; Morgan EM;
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 32396520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the value of symptom relief for patients with gastroesophageal reflux disease treatment: willingness to pay using a discrete choice experiment.
    Deal K; Marshall D; Dabrowski D; Charter A; Bukoski M; Moayyedi P
    Value Health; 2013 Jun; 16(4):588-98. PubMed ID: 23796293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database.
    Minden K; Niewerth M; Listing J; Möbius D; Thon A; Ganser G; Ermisch-Omran B; Zink A
    Clin Exp Rheumatol; 2009; 27(5):863-9. PubMed ID: 19917175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Juvenile idiopathic arthritis and malignancy.
    Ruperto N; Martini A
    Rheumatology (Oxford); 2014 Jun; 53(6):968-74. PubMed ID: 24185766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey.
    Currie GR; Groothuis-Oudshoorn CGM; Twilt M; Kip MMA; IJzerman MJ; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung R; Marshall DA
    Clin Rheumatol; 2023 Aug; 42(8):2173-2180. PubMed ID: 37202606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Access to biologic therapies in Canada for children with juvenile idiopathic arthritis.
    Leblanc CM; Lang B; Bencivenga A; Chetaille AL; Dancey P; Dent P; Miettunen P; Oen K; Rosenberg A; Roth J; Scuccimarri R; Tse SM; Benseler S; Cabral DA; Campillo S; Chédeville G; Duffy CM; Duffy KW; Haddad E; Huber AM; Laxer R; Levy D; Johnson N; Ramsey S; Shiff N; Schmeling H; Schneider R; Stringer E; Yeung RS; Tucker LB
    J Rheumatol; 2012 Sep; 39(9):1875-9. PubMed ID: 22859344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Juvenile idiopathic arthritis--current and future therapies.
    Kahn P
    Bull NYU Hosp Jt Dis; 2009; 67(3):291-302. PubMed ID: 19852753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry.
    Drechsel P; Stüdemann K; Niewerth M; Horneff G; Fischer-Betz R; Seipelt E; Spähtling-Mestekemper S; Aries P; Zink A; Klotsche J; Minden K
    Rheumatology (Oxford); 2020 Mar; 59(3):603-612. PubMed ID: 31412128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current therapy of polyarticular forms of juvenile idiopathic arthritis].
    Hospach A; Rühlmann JM; Weller-Heinemann F
    Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment.
    Augustovski F; Beratarrechea A; Irazola V; Rubinstein F; Tesolin P; Gonzalez J; Lencina V; Scolnik M; Waimann C; Navarta D; Citera G; Soriano ER
    Value Health; 2013; 16(2):385-93. PubMed ID: 23538191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Considerations for the Primary Care Provider Caring for Patients with Juvenile Idiopathic Arthritis Receiving Biologic Therapy.
    Zic C
    Pediatr Ann; 2022 Feb; 51(2):e54-e56. PubMed ID: 35156891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.